Get the Stockscreener App
47.75
0.20%
-0.03
Sanofi Adr stock is traded at $47.75, with a volume of 118.45K.
It is down -0.20% in the last 24 hours and down -11.13% over the past month.
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
See More
Previous Close:
$47.78
Open:
$47.64
24h Volume:
118.45K
Relative Volume:
0.07
Market Cap:
$120.15B
Revenue:
$53.04B
Net Income/Loss:
$4.93B
P/E Ratio:
15.05
EPS:
3.1735
Net Cash Flow:
$15.63B
1W Performance:
-0.28%
1M Performance:
-11.13%
6M Performance:
-2.58%
1Y Performance:
+2.44%
1-Day Range:
$47.56
$47.76
1-Week Range:
$47.45
$48.67
52-Week Range:
$45.22
$58.97
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SNY | 47.74 | 120.15B | 53.04B | 4.93B | 15.63B | 3.1735 |
| LLY | 745.83 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 102.31 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 153.32 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 167.99 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 97.58 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Reiterated | Argus | Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
Weekly Upgrades and Downgrades - InvestorPlace
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease - Benzinga
Communiqué de presse - GlobeNewswire Inc.
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
Here’s Why Mastercard Incorporated (NYSE: MA) Is An Attractive Investment Right Now - Stocks Register
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo Finance
16 New 4-Star Stocks - Morningstar
Sanofi SA (ADR: SNY) Stock Price Could Reach $63: Morningstar Research - TopNews India
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - MSN
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat - Investor's Business Daily
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Sanofi, HCA, Colgate-Palmolive lead Friday's earnings lineup By Investing.com - Investing.com Australia
Sanofi, HCA, Colgate-Palmolive lead Friday's earnings lineup - Investing.com
Sanofi Deal Jitters Imperil Stock’s Big Rebound - MSN
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale - Zacks Investment Research
Proactive news headlines: Ananda, Helix Exploration, Deltic, Light Science Technologies and more - Proactive Investors UK
French govt set to take stake in Sanofi unit after PE sale - Proactive Investors Australia
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Sanofi ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Ratios Reveal: Breaking Down Sanofi ADR (SNY)’s Financial Health - The Dwinnex
EXK (Endeavour Silver Corp.) may reap gains as insiders became active recently - Knox Daily
Checking in on Clear Channel Outdoor Holdings Inc. (CCO) after recent insiders movement - Knox Daily
Investing in Sanofi ADR (SNY): What You Must Know - Knox Daily
Investing in Replimune Group Inc (REPL) Is Getting More Attractive - Knox Daily
An Analysis of KE Holdings Inc ADR (BEKE)’s Potential Price Growth - Knox Daily
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
OTC Drug and Dietary Supplement Market Opportunities and Strategies to 2033 - GlobeNewswire Inc.
Precidian to List First ADRhedged Securities in the U.S. on Cboe, Providing Exposure to Individual International Companies with an Embedded Currency Hedge - PR Newswire
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):